Polymerase News and Research

RSS

Boehringer Ingelheim's STARTVerso 1 Phase 3 hepatitis C data to be presented at EASL Congress

Boehringer Ingelheim today announced that data from its pivotal STARTVerso 1 Phase 3 hepatitis C clinical trial have been accepted for oral presentation as a late-breaker at the International Liver Congress 2013: 48th Annual Meeting of the European Association for the Study of the Liver, taking place from April 24-28 in Amsterdam, The Netherlands.

10 Apr 2013

Abstracts on Bristol-Myers Squibb's research in liver disease accepted for presentation

Bristol-Myers Squibb Company announced today that 14 abstracts on the Company's research in liver disease have been accepted for presentation at The International Liver CongressTM 2013, the 48th annual meeting of the European Association for the Study of the Liver, in Amsterdam, April 24 - 28.

8 Apr 2013

Vertex to conduct two Phase 2 studies of VX-135 in combination with daclatasvir

Vertex Pharmaceuticals Incorporated today announced it has entered into a non-exclusive agreement with Bristol-Myers Squibb Company to conduct Phase 2 studies of once-daily all-oral treatment regimens containing Vertex's nucleotide analogue hepatitis C virus polymerase inhibitor VX-135 and Bristol-Myers Squibb's NS5A replication complex inhibitor daclatasvir for the treatment of hepatitis C.

6 Apr 2013

Researchers diagnose genetic disease in embryonic DNA without biopsy

Preimplantation genetic diagnosis (PGD) technologies allow identification of genetic disorders in human preimplantation embryos after in vitro fertilization (IVF) and before the embryo is transferred back to the patient.

3 Apr 2013

PARP inhibitors can be novel treatment strategy for cisplatin-resistant cancer

Poly (ADP-ribose) polymerase inhibitors may be a novel treatment strategy for patients with cancer that has become resistant to the commonly used chemotherapy drug cisplatin, according to data from a preclinical study published in Cancer Research, a journal of the American Association for Cancer Research.

3 Apr 2013

New screening procedure determines animal, plant, and microbial substances in foodstuffs

Scientists at the Institute of Molecular Genetics, Genetic Security Research and Consulting at Johannes Gutenberg University Mainz (JGU) have developed a novel screening procedure that provides for highly sensitive, quantifiable analysis of animal, plant, and microbial substances present in foodstuffs.

28 Mar 2013

New vaccine proves highly effective against H5N1 virus

Until now most experimental vaccines against the highly lethal H5N1 avian influenza virus have lacked effectiveness. But a new vaccine has proven highly effective against the virus when tested in both mice and ferrets. It is also effective against the H9 subtype of avian influenza.

26 Mar 2013

Researchers develop single molecule test for detecting methylated DNA

Collaborators from Mayo-Illinois Alliance for Technology Based Healthcare have developed a new, single molecule test for detecting methylated DNA. Methylation -- the addition of a methyl group of molecules to a DNA strand -- is one of the ways gene expression is regulated.

15 Mar 2013

Discovery provides clues for potentially eliminating HIV infection in children

A two-year-old child born with HIV infection and treated with antiretroviral drugs beginning in the first days of life no longer has detectable levels of virus using conventional testing despite not taking HIV medication for 10 months, according to findings presented today at the Conference on Retroviruses and Opportunistic Infections in Atlanta.

5 Mar 2013

UMDNJ biochemist to research into mechanisms that control gene expression in mitochondria

Dmitry Temiakov, PhD, a biochemist at the University of Medicine and Dentistry of New Jersey-School of Osteopathic Medicine, has received a five-year, $1.5 million grant from the National Institutes of Health (NIH) to fund research into the molecular mechanisms that control gene expression in mitochondria, the organelles that are the "power plants" of cellular activity.

1 Mar 2013

Three Robert Wood Johnson members win Edward J. Ill Excellence in Medicine Awards

Three members of the University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School faculty have been named 2013 recipients of the prestigious Edward J. Ill Excellence in Medicine Awards, highlighting their expertise as exceptional educators or researchers.

1 Feb 2013

Dectin-1 potential target for nasal polyposis

The transmembrane protein Dectin-1 appears to play a role in the pathogenesis of nasal polyposis, providing a potential new target for treating the condition, report Chinese researchers.

29 Jan 2013

Janssen, Medivir and Idenix partner for clinical development of HCV combination therapy

Medivir AB today announced a non-exclusive collaboration between Janssen Pharmaceuticals Inc. (Janssen) and Idenix Pharmaceuticals for the clinical development of an all-oral (interferon-free) direct-acting antiviral (DAA) hepatitis C (HCV) combination therapy.

29 Jan 2013

ParseCNV software can detect disease-causing copy number variations

A novel software tool, developed at The Children's Hospital of Philadelphia, streamlines the detection of disease-causing genetic changes through more sensitive detection methods and by automatically correcting for variations that reduce the accuracy of results in conventional software.

22 Jan 2013

Researchers identify and test first blood-based circulating miRNA biomarkers for Parkinson's

Parkinson's disease (PD) is a progressive neurological condition. At present, it is usually diagnosed only when motor features are present. Hence, there is a need to develop objective and measurable biomarkers to improve PD diagnostics during its earlier stage, prior to its motor onset. In this pilot study, researchers identified and tested the first blood-based circulating microRNA (miRNA) biomarkers for PD.

21 Jan 2013

Boehringer Ingelheim initiates enrollment in Phase III IFN-free HCV trial

Today, Boehringer Ingelheim announced that the first patients have been enrolled in the company's pivotal Phase III interferon (IFN)-free hepatitis C (HCV) clinical trial programme, HCVerso.

18 Jan 2013

Life Technologies, ASU partner on new project to quickly measure radiation exposure

Arizona State University's Biodesign Institute- has announced a partnership with Life Technologies Corporation as it enters the next phase of a multi-million-dollar, multi-institutional research project to develop a medical device to rapidly assess an individual's exposure to radiation in the event of a nuclear incident.

18 Jan 2013

Human papillomavirus an etiologic factor in 6% of OCSCC cases

High-risk human papillomavirus is an etiologic factor in approximately 6% of cases of oral cavity squamous cell carcinoma, according to epidemiologic research.

14 Jan 2013

UMDNJ develops rapid detection test for Exserhilum rostratum

A rapid detection test for Exserhilum rostratum, the fungus primarily responsible for 39 deaths among patients injected last year with a contaminated steroid medication, has been developed by a research team led by David S. Perlin, PhD, Executive Director of the Public Health Research Institute (PHRI) at the University of Medicine and Dentistry of New Jersey-New Jersey Medical School.

10 Jan 2013

Simple and inexpensive method to cut DNA could transform genetic medicine

A simple, precise and inexpensive method for cutting DNA to insert genes into human cells could transform genetic medicine, making routine what now are expensive, complicated and rare procedures for replacing defective genes in order to fix genetic disease or even cure AIDS.